ONPH — Oncology Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Oncology Pharma, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2002 March 31st	2003 March 31st	2004 March 31st	2011 June 30th	2013 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10KSB	10KSB	10KSB	PRESS	ARS
Standards:	USG	USG	USG	—	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	3.67	3.28	1.18	0.135	0.01
Cost of Revenue
Gross Profit	2.31	2.07	0.527	—	—
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	5.69	4.91	2.88	0.075	0.226
Operating Profit	-2.02	-1.63	-1.7	0.06	-0.216
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1.95	-1.52	-1.56	0.06	-0.185
Provision for Income Taxes
Net Income After Taxes	-1.95	-1.52	-1.56	0.059	-0.186
Net Income Before Extraordinary Items
Net Income	-1.95	-1.52	-1.56	0.059	-0.186
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-1.95	-1.52	-1.56	0.059	-0.186
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-119,327,217	-81,196,581	-74,737,303	852,817	-66,983
Dividends per Share